• Nardi Tetaj, Pierluca Piselli, Sara Zito, Giada De Angelis, Maria Cristina Marini, Dorotea Rubino, Ilaria Gaviano, Maria Vittoria Antonica, Elisabetta Agostini, Candido Porcelli, Giulia Valeria Stazi, Gabriele Garotto, Donatella Busso, Silvana Scarcia, Assunta Navarra, Claudia Cimaglia, Simone Topino, Fabio Iacomi, Alessandra D'Abramo, Carmela Pinnetti, Gina Gualano, Alessandro Capone, Alberta Villanacci, Andrea Antinori, Fabrizio Palmieri, Gianpiero D'Offizi, Stefania Ianniello, Fabrizio Taglietti, Paolo Campioni, Francesco Vaia, Emanuele Nicastri, Enrico Girardi, Luisa Marchioni, and On Behalf Of The ReCOVeRI Study Group.
• UOC Resuscitation, Intensive and Sub-Intensive Care, National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, 00149 Rome, Italy.
• Medicina (Kaunas). 2022 Aug 15; 58 (8).

AbstractBackground and Objectives: Background: Coronavirus disease 2019 (COVID-19) is a novel cause of Acute Respiratory Distress Syndrome (ARDS). Noninvasive ventilation (NIV) is widely used in patients with ARDS across several etiologies. Indeed, with the increase of ARDS cases due to the COVID-19 pandemic, its use has grown significantly in hospital wards. However, there is a lack of evidence to support the efficacy of NIV in patients with COVID-19 ARDS. Materials and Methods: We conducted an observational cohort study including adult ARDS COVID-19 patients admitted in a third level COVID-center in Rome, Italy. The study analyzed the rate of NIV failure defined by the occurrence of orotracheal intubation and/or death within 28 days from starting NIV, its effectiveness, and the associated relative risk of death. The factors associated with the outcomes were identified through logistic regression analysis. Results: During the study period, a total of 942 COVID-19 patients were admitted to our hospital, of which 307 (32.5%) presented with ARDS at hospitalization. During hospitalization 224 (23.8%) were treated with NIV. NIV failure occurred in 84 (37.5%) patients. At 28 days from starting NIV, moderate and severe ARDS had five-fold and twenty-fold independent increased risk of NIV failure (adjusted odds ratio, aOR = 5.01, 95% CI 2.08−12.09, and 19.95, 95% CI 5.31−74.94), respectively, compared to patients with mild ARDS. A total of 128 patients (13.5%) were admitted to the Intensive Care Unit (ICU). At 28-day from ICU admission, intubated COVID-19 patients treated with early NIV had 40% lower mortality (aOR 0.60, 95% CI 0.25−1.46, p = 0.010) compared with patients that underwent orotracheal intubation without prior NIV. Conclusions: These findings show that NIV failure was independently correlated with the severity category of COVID-19 ARDS. The start of NIV in COVID-19 patients with mild ARDS (P/F > 200 mmHg) appears to increase NIV effectiveness and reduce the risk of orotracheal intubation and/or death. Moreover, early NIV (P/F > 200 mmHg) treatment seems to reduce the risk of ICU mortality at 28 days from ICU admission.

19 keywords...

hide…